We show that absolute and severe neutropenia after high-dose therapy with melphalan with or without total body irradiation can be abrogated by cells generated ex vivo. This may change the clinical practice of haematopoietic cell transplantation and high-dose chemotherapy because the morbidity and hospitalisation associated with neutropenia could be avoided or reduced.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(99)03113-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
J Mol Med (Berl)
April 2013
Cancer Center, Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, USA.
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Combining passive immunotherapy with an antibody to the disialoganglioside GD2 (ch14.18/SP2/0) and cytokines with 13-cis-retinoic acid for post-myeloablative maintenance therapy increased survival in high-risk NB, but the overall prognosis for these children is still in need of improvement.
View Article and Find Full Text PDFWe show that absolute and severe neutropenia after high-dose therapy with melphalan with or without total body irradiation can be abrogated by cells generated ex vivo. This may change the clinical practice of haematopoietic cell transplantation and high-dose chemotherapy because the morbidity and hospitalisation associated with neutropenia could be avoided or reduced.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!